A new dawn in research: FDA approves pegulicianine for fluorescence-guided surgery in breast cancer patients

作者
Muhammad Faateh Sajid,Muhammad Shoaib Hussain,Muhammed Aalam Shah,Muhammad Haseef Awan,Fnu Muskan,Afshan Tarannum Mohammad,Syeed Mahmud Nishat
出处
期刊:Annals of medicine and surgery [Wolters Kluwer]
卷期号:87 (3): 1097-1100 被引量:13
标识
DOI:10.1097/ms9.0000000000002980
摘要

Introduction Roughly 1.7 million new cases of breast cancer are recognized annually, making it the most frequent disease among women worldwide. Significant differences exist in incidence rates, with remarkable rates (92 per 100 000) in prosperous countries for example North America and lower rates (27 per 100 000) in impoverished places such as Middle Africa. Geographical divagation exists, but across the board, breast cancer incidence and death rise with age and peak at 60 years of age. For instance, women between the ages of 20 and 44 obtain a larger proportion of diagnoses in Latin America. Still, women in Asia and Africa usually receive a diagnosis between the ages of 40 and 50[1]. A lumpectomy, which eradicates the tumor along with some encircling normal tissue, and a mastectomy, which removes the breast, are the alternative surgical treatments functional for early-stage breast cancer. Studies have proposed that the two surgical procedures are equivalent in recent decades, and both have been widely conducted in clinical settings[2]. The most reliable indicator of local recurrence is the tumor’s existence at the lumpectomy margins. It is challenging to execute entire tumor excision during breast-conserving surgery (BCS) because preoperative imaging and contemporary intraoperative assessment procedures do not reliably detect the microscopic magnitude of malignancies. To overcome this obstacle, Lumicell has built a novel fluorescence-guided system (FGS) that comprises a patient-specific tumor identification algorithm, a portable device, and an activatable fluorescent imaging agent (pegulicianine)[3]. Fluorescence-guided lumpectomy Fluorescence-guided lumpectomy is a refined surgical procedure that employs fluorescence imaging to visualize cancerous tissue in real-time, enhancing the precision of breast cancer surgery. This technique aims to enhance the precision of tumor resection by removing all cancerous cells while preserving healthy breast tissue, thereby lowering the risk of cancer recurrence and the need for additional procedures[4]. Traditional methods of breast cancer surgery often depend on visual and tactile cues, which can be insufficient due to tumor variation and proximity to healthy tissues[5]. The fluorescence-guided technique involves using fluorescent dyes, such as pegulicianine, that stick to cancer cells and exhibit fluorescence upon exposure to a specific wavelength of light. During surgery, surgeons employ specialized imaging equipment to identify this fluorescence, providing real-time guidance to ensure full removal of cancerous tissue[6]. This technique not only enhances tumor vision but also assists in achieving cleaner surgical margins, which is critical for minimizing the possibility of remaining malignancy and the need for further surgeries[7]. Currently, several fluorescent dyes and contrast agents are employed to assist surgeons in differentiating cancerous tissue from healthy breast tissue during surgery. Indocyanine green is a well-established substance that emits near-infrared fluorescence, aiding in the visualization of lymphatic drainage and tumor boundaries[8]. Another important component is 5-aminolevulinic acid, which transforms into protoporphyrin IX in cancer cells and glows when exposed to blue light, helping to distinguish cancerous tissue[9]. Fluorescein, a vibrant green dye, is mainly used to evaluate blood circulation and lymphatic vessels, although it is not frequently utilized for directly imaging tumors[10]. Moreover, near-infrared dyes like Cy5.5 and Cy7 provide greater tissue penetration and less background interference, which is beneficial for accurate imaging in research and medical environments[11]. Quantum dots have adjustable fluorescence properties that offer bright and stable visualization of tumors[12], while BODIPY dyes provide high brightness and stability for potential use in surgical imaging[13]. Acridine orange, a dye that binds to nucleic acids, is mainly utilized in research but shows potential for improving tissue visibility in medical applications[14]. Techniques for fluorescence-guided lumpectomy are constantly advancing. Pegulicianine, a recent innovation, has shown significant advances in visualizing cancerous tissue compared to older methods. Its combination with other imaging modalities, such as ultrasound and MRI, further enhances surgical precision[15]. Despite its potential advantages, the technology encounters problems such as the need for specialized equipment and discrepancies in dye performance, which an ongoing study aims to solve[16]. Lastly, fluorescence-guided lumpectomy is an important leap ahead in the surgical management of breast cancer, promising precise tumor removal and improved patient outcomes. The technique incorporates real-time fluorescence imaging into surgical practice and sets a new benchmark for precision and effectiveness in breast cancer treatment[17]. Pegulicianine mechanism of action The FDA approved Pegulicianine (Lumisight) and the Lumicell Direct Visualization System, collectively referred to as LumiSystem, in April 2024. It is the world’s first-ever imaging combination product that detects cancerous tissue inside the breast cavity during a lumpectomy surgery and aids in avoiding second surgeries[18]. Pegulicianine is an inactive drug (prodrug) composed of three major components; one contains a quenching agent that renders the intact molecule optically dormant. Furthermore, enzyme breakdown of the prodrug yields two optically active fragments that transmit a signal identified using a fluorescence imaging system[19]. Pegulicianine’s mode of action is both advanced and interesting. It is a photosensitizing agent and is more readily taken up by neoplastic cells because of their high metabolic rates and propensity to particular chemicals. It builds up in the cancer cells, effectively identifying cancer cells for further light therapy. When the drug experiences exposure to a particular wavelength of light, usually in the red range, a light-induced reaction takes place. This process generates free radicals, specifically singlet oxygen, which is lethal. These reactive oxygen derivatives destroy cell organelles and components like the plasma membrane, mitochondria, and deoxyribonucleic acid, destroying the cell. This precise elimination of malignant cells reduces surrounding injury to nearby cells, which is a typical problem with traditional chemotherapeutics and radiotherapy. Moreover, the elimination of malignant cells results in cancer antigen release, which triggers the immune system to recognize and fight remaining cancer cells. This pegulicianine’s double action (direct cytotoxicity and immunological activation) makes it a strong weapon in oncology[20]. The recommended dosage of pegulicianine is one milligram per kilogram (1 mg/kg) of actual body weight given intravenously for 3 minutes, 2–6 hours before imaging[21]. The most common side effect of pegulicianine is hypersensitivity, while uncommon side effects include chest tightness, fatigue, and cough. The most serious complication of using pegulicianine is an anaphylactic reaction[22]. Clinical trials on pegulicianine FDA approval was based on the Phase 3 INSITE trial (NCT03686215), which treated 406 patients with 1.0 mg/kg of pegulicianine intravenously followed by lumpectomy. The study evaluated key endpoints, including the percentage of patients for whom pegulicianine fluorescence-guided system (pFGS)—guided margins contained cancer, sensitivity, and specificity. Results indicated that the margin-level specificity of pegulicianine-guided surgery was 85.2% (95% CI, 83.7–86.6%), while the sensitivity was 49.3% (95% CI, 37.0–61.6%]. Signals from pegulicianine were used in the resection of residual tumors in 27 of 357 patients, while a second surgery was avoided in 9 of 62 with positive margins. Secondary endpoints in the trial included the rate at which margins were positive and what effect pegulicianine-guided margins would have on the volume of tissue excised. Patients with invasive breast cancer or ductal carcinoma in situ aged 18 years and above were eligible for this study. Those who had previously received neoadjuvant therapy or excision of margins after previous lumpectomy were not allowed to participate in this study. As many as 1.5% of the patients involved in the trial were taken off pegulicianine because of adverse events that were experienced in the course of this study. This included two patients developing serious grade three events, which were hypersensitivity and anaphylaxis. All toxicities resolved, and patients went on to undergo their planned surgery. Results of the trial met prespecified thresholds for specificity and tumor resection, demonstrating the potential of LumiSystem to enhance accuracy during surgery and improve patient outcomes in breast cancer surgery[23]. In a recent prospective single-arm open-label trial (NCT03321929) which includes 283 patients across 16 U.S. breast medical centers, the pFGS was assessed for its safety and efficacy in BCS. With a false-negative rate of 23.7%, the procedure exhibited a significant rise in sensitivity (69.4%) higher than traditional pathology (38.2%). Notably, in 19% of cases, the necessity for re-excision was prevented by using pFGS to direct further tissue removal. These findings imply that pFGS is an effective procedure for enhancing surgical outcomes in BCS, highlighting the need for more clinical research[3]. Table 1 summarizes pegulicianine fluorescence-guided clinical trials in breast cancer surgery patients. Table 1 - Summary of pegulicianine fluorescence-guided clinical trials in breast cancer surgery. Aspect INSITE Phase 3 Trial (NCT03686215) INSITE nonrandomized controlled trial (NCT03321929) Objective To evaluate if pegulicianine fluorescence-guided surgery (pFGS) can improve detection and removal of residual tumor in patients undergoing breast-conserving surgery. To assess the safety and initial efficacy of pegulicianine fluorescence-guided system (pFGS) for identifying residual cancer in the tumor bed during breast-conserving surgery (BCS). Study design Prospective, multicenter, randomized (10:1), involving 406 patients with stages 0–3 breast cancer. Prospective, single-arm, non-randomized multicenter trial at 16 breast centers in the US, with 283 female patients enrolled. Interventions Patients received 1.0 mg/kg IV pegulicianine followed by standard lumpectomy. pFGS-guided cavity margins were excised where pegulicianine signal indicated tumor presence. Patients received 1.0 mg/kg pegulicianine injection approximately 3.2 hr prior to surgery. After standard excision, pFGS was used to assess the lumpectomy cavity for further margin removal. Results Residual tumors were removed in 27 of 357 patients using pFGS-guided margins. Sensitivity improved to 69.4% compared to standard pathology (38.2%). False-negative rate: 23.7% Specificity: 85.2% pFGS averted re-excision in 19% of patients. Sensitivity: 49.3%. Adverse events 6 patients discontinued pegulicianine due to adverse events. Two patients experienced serious grade 3 events (hypersensitivity and anaphylaxis). 1 patient had an anaphylactic reaction but recovered without sequelae. Overall safety profile was consistent with other imaging agents used in BCS. Conclusions pFGS was effective in identifying residual tumor and avoiding second surgeries, meeting specificity but not sensitivity thresholds. pFGS was associated with reduced need for re-excision and improved intraoperative cancer detection. Further randomized trials are recommended. Future of pegulicianine Future research in pFGS needs to address several limitations to enhance its clinical utility. The relatively lower sensitivity of the system, as demonstrated in current trials, highlights the need for optimization, particularly in detecting microscopic residual disease or small, complex tumor structures. Ongoing studies, such as NCT04440982, should focus on collecting additional tissue samples from both pFGS-positive and pFGS-negative areas to improve sensitivity calculations and refine the detection algorithm[23]. An important consideration in fluorescence-guided surgery is the influence of the extracellular matrix (ECM) on fluorescence signal intensity and distribution. The ECM in tumor tissues often exhibits distinct characteristics, such as increased stiffness and altered protease activity, which can modulate the optical properties of imaging agents like pegulicianine. These variations may affect fluorescence signal strength, particularly in dense or desmoplastic tumors, emphasizing the need for continued optimization of imaging protocols and agents[24,25]. Pegulicianine in conjunction with other imaging techniques, such as MRI or ultrasound, can also be explored further for improved intraoperative guidance. Similarly, other areas of potential that hold great promise for clinical utility involve developing personalized dosing protocols and expanding their use from the management of breast cancer to other types of solid tumors. The efficacies of such guidance in long-term outcomes, such as the recurrence rate and overall survival of patients undergoing pFGS-guided lumpectomies, would yield very important real-time data for this approach in reducing the burden of cancer recurrence. Finally, variability in dye performance and refinement of the fluorescence technology could make this innovative tool accessible to a wider range of surgical settings and thus maximize its full potential in oncologic surgery.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
隐形曼青的应助被好好好采纳,获得10
刚刚
铎铎铎完成签到 ,获得积分0
刚刚
刚刚
decimalpoint完成签到,获得积分10
刚刚
enen发布了新的文献求助10
1秒前
didi发布了新的文献求助30
3秒前
feifei发布了新的文献求助10
3秒前
yy发布了新的文献求助10
4秒前
orixero的应助被Kiki采纳,获得10
4秒前
凉白开完成签到,获得积分10
4秒前
4秒前
汉堡包的应助被小瑶采纳,获得10
4秒前
4秒前
思源的应助被秦志文采纳,获得10
5秒前
5秒前
蓝天发布了新的文献求助200
5秒前
wuliweiwei完成签到,获得积分10
6秒前
7秒前
陈雅茹发布了新的文献求助10
7秒前
希望天下0贩的0的应助被墨白采纳,获得10
7秒前
Hello的应助被科研通管家采纳,获得10
7秒前
完美世界的应助被科研通管家采纳,获得10
7秒前
NexusExplorer的应助被科研通管家采纳,获得10
7秒前
C.Cat的应助被科研通管家采纳,获得10
8秒前
桐桐的应助被科研通管家采纳,获得10
8秒前
爆米花的应助被科研通管家采纳,获得10
8秒前
8秒前
CipherSage的应助被科研通管家采纳,获得10
8秒前
小杨梅发布了新的文献求助10
8秒前
8秒前
情怀的应助被科研通管家采纳,获得10
8秒前
NexusExplorer的应助被科研通管家采纳,获得10
8秒前
SciGPT的应助被科研通管家采纳,获得10
8秒前
C.Cat的应助被科研通管家采纳,获得10
9秒前
YYM完成签到 ,获得积分10
9秒前
9秒前
十三月发布了新的文献求助10
10秒前
cherry完成签到,获得积分10
10秒前
int0发布了新的文献求助10
10秒前
nansang发布了新的文献求助10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153492
求助须知:如何正确求助?哪些是违规求助? 9550166
关于积分的说明 21696892
捐赠科研通 7742051
什么是DOI,文献DOI怎么找? 3425502
关于科研通互助平台的介绍 2550620
邀请新用户注册赠送积分活动 2469156